Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient

Reuters

2025/10/02

<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient

Kazia Therapeutics Limited (NASDAQ: KZIA) has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer (TNBC) treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab (Keytruda®) and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89222) on October 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572129505"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572129505\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572129505?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572129505","market":"fut","top_or_hot":-1,"title":"Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> (NASDAQ: KZIA) has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer (TNBC) treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab (Keytruda®) and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89222) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-02 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> (NASDAQ: KZIA) has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer (TNBC) treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab (Keytruda®) and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89222) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL1LQL4Z:1","article_id":"2572129505","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572129505","pubTimestamp":1759408247,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient. Kazia Therapeutics Limited  has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer  treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab  and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KZIA":"Kazia Therapeutics Limited"},"translate_title":"Kazia Therapeutics宣布Paxalisib联合疗法治疗晚期乳腺癌的1b期试验取得有希望的结果，报告转移性TNBC患者肿瘤减少86%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"Kazia Therapeutics Announces Promising Results in Phase 1b Trial for Paxalisib Combination Therapy in Advanced Breast Cancer, Reports 86% Tumor Reduction in Metastatic TNBC Patient\n    \n\nKazia Therapeutics Limited (NASDAQ: KZIA) has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer (TNBC) treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab (Keytruda®) and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89222) on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}